Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 6/20 | 0.41 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4030200 | 0.89 | MAPK1 (0.48) | MAPK1BRD4CREBBPNPC1ALDH1A1 | |
| SCHEMBL4713062 | 0.86 | MAPK1 (0.67) | MAPK1BRD4CREBBPNPC1ALDH1A1 | |
| SCHEMBL1336775 | 0.84 | MAPK1 (0.56) | MAPK1BRD4CREBBPNPC1ESR2 | |
| SCHEMBL2073836 | 0.83 | MAPK1 (0.49) | MAPK1BRD4CREBBPNPC1HMOX1 | |
| SCHEMBL4712216 | 0.83 | MAPK1 (0.56) | MAPK1BRD4CREBBPNPC1ESR2 | |
| SCHEMBL4762437 | 0.83 | MAPK1 (0.72) | MAPK1BRD4CREBBPNPC1 | |
| SCHEMBL2975661 | 0.83 | MAPK1 (0.56) | MAPK1BRD4CREBBPNPC1ESR2 | |
| SCHEMBL10095067 | 0.82 | BRD4 (0.67) | MAPK1BRD4CREBBPNPC1 | |
| SCHEMBL10211781 | 0.81 | MAPK1 (0.55) | MAPK1BRD4CREBBPNPC1 | |
| SCHEMBL2977256 | 0.81 | MAPK1 (0.57) | MAPK1BRD4CREBBPNPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772236-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7589202-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080300255-A1 | Substituted pyrazoles | BEAVERS MARY PAT | 2008-12-04 | — | — | US | disclosed |
| US-20080293732-A1 | Substituted pyrazoles | BEAVERS MARY PAT | 2008-11-27 | — | — | US | disclosed |
| US-7452890-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7429591-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7417046-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| US-7393850-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-01 | — | — | US | disclosed |
| US-7388011-B2 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-7332494-B2 | Method for treating allergies using substituted pyrazoles | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-02-19 | — | — | US | disclosed |
| US-20070004738-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2007-01-04 | — | — | US | disclosed |
| US-20070004754-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-1315491-B1 | USE OF SUBSTITUTED PYRAZOLES FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ALLERGIES | ORTHO MCNEIL PHARM INC (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1315491-A2 | METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1309591-A2 | SUBSTITUTED PYRAZOLES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030073672-A1 | Method for treating allergies using substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2003-04-17 | — | — | US | disclosed |
| US-20030069240-A1 | Method for treating allergies using substituted pyrazoles | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-04-10 | — | — | US | disclosed |
| US-20020040020-A1 | Substituted pyrazoles | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-04-04 | — | — | US | disclosed |
| WO-2002020012-A2 | METHOD FOR TREATING ALLERGIES USING SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002014314-A2 | SUBSTITUTED PYRAZOLES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293732-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | MAPK1 4519/4885BRD4 605/4885CREBBP 2922/4885 |
| US-20080300255-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | MAPK1 4519/4885BRD4 605/4885CREBBP 2922/4885 |
| US-20070004738-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | MAPK1 4519/4885BRD4 605/4885CREBBP 2922/4885 |
| US-20030069240-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | MAPK1 4370/4885BRD4 140/4885CREBBP 1005/4885 |
| US-20030073672-A1 | Method for treating allergies using substituted pyrazoles | TSLP, IL33, HRH2 | MAPK1 4370/4885BRD4 140/4885CREBBP 1005/4885 |
| US-20070004754-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSB | MAPK1 4519/4885BRD4 605/4885CREBBP 2922/4885 |
| US-20020040020-A1 | Substituted pyrazoles | CTSS, CTSZ, CTSV | MAPK1 4426/4885BRD4 866/4885CREBBP 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.